证券代码：000566 证券简称：海南海药 海南海药股份有限公司 口服 2.5-25 mg 派恩加滨片后，药物迅速吸收，并 迅速生成代谢产物，两者均在达峰后快速分布，随后缓慢 消除。派恩加滨极少以原型形式从尿液中排泄，少量以代 谢产物形式从尿液排泄。食物影响研究显示食物会延长派 恩加滨及其代谢产物的 Tmax，但对于派恩加滨及其代谢 物的 PK 暴露量影响较小。 安全性情况：研究中无受试者发生 DLT、不良事件通 用术语标准(CTCAE)≥3 级的 TEAE、导致死亡的 TEAE、 严重给药期间不良事件(STEAE)和导致退出研究的 TEAE 或特别关注的不良事件(AESI)。 3、派恩加滨 Ib 期临床研究药代动力学结果和安全性 结果？ 回复：健康成年受试者口服派恩加滨后，可以迅速生 成代谢产物，多次剂量递增试验日总剂量 10mg~15mg 剂量 范围内派恩加滨以及代谢产物在连续用药 8-9 天后，其血 药浓度均已处于稳态，血药浓度及暴露量均随着剂量的增 加而逐渐提高。 所有受试者均未发生 SAE、SADR、>3 级的 TEAE 及 ADR、 导致退出试验的 TEAE 及 ADR。 4、派恩加滨Ⅱa 期疗效 ...

Group 1 - The company, Fujian Cosunter Pharmaceutical Co., Ltd., plans to issue A-shares to specific investors, with the proposal approved by the board and shareholders [2][3] - The issuance will target no more than 35 specific investors, including qualified institutional investors and individuals, with all subscriptions to be made in cash [3][4] - The pricing for the shares will be based on the average trading price over the 20 trading days prior to the pricing date, set at no less than 80% of that average [4] Group 2 - The total number of shares to be issued will not exceed 47,780,100, representing no more than 30% of the company's total share capital prior to the issuance [5] - The company aims to raise up to 976.87 million yuan, with funds allocated primarily for innovative drug research and development, traditional Chinese medicine industrialization, and working capital [5] - The company will initially use self-raised funds for projects until the raised funds are available, and if the actual net amount raised is less than planned, adjustments will be made based on project priorities [5] Group 3 - After the issuance, the shares subscribed by investors will be subject to a six-month lock-up period [6] - The issuance will not change the controlling shareholder or the actual controller of the company, nor will it affect the distribution of shares in a way that violates listing conditions [6] - The company has committed to measures to compensate for any dilution of immediate returns resulting from the issuance [6] Group 4 - The company has experienced continuous losses, with net profits of -132.18 million yuan, -354.23 million yuan, -199.54 million yuan, and -30.42 million yuan in recent periods, primarily due to increased R&D investments and price declines from centralized procurement policies [10][11] - The company is focusing on innovative drug development, which typically involves high costs and long timelines, and faces risks related to market acceptance and competition [9][10] - The company has established itself as a well-known player in the antiviral drug market, particularly in hepatitis B treatment, with a product portfolio that includes generics and innovative drugs [14]